| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $132.6M | — | +158.7% |
| SG&A Expense | $62.6M | — | +301.6% |
| Net Income | -$189.4M | — | -201.1% |
| EPS (Basic) | -$0.24 | — | -166.7% |
| EPS (Diluted) | -$0.24 | — | -166.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $106.5M | -52.7% | -49.6% |
| Short-term Investments | $492.2M | +0.8% | +228.6% |
| Current Assets | $616.6M | -14.4% | +66.3% |
| Total Assets | $647.9M | -13.8% | +68.8% |
| Current Liabilities | $83.3M | +14.1% | +138.7% |
| Total Liabilities | $101.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$122.3M | — | -99.9% |
| Capital Expenditures | $245K | — | -41.9% |
| Investing Cash Flow | -$238K | — | -100.1% |
| Financing Cash Flow | $3.8M | — | -50.5% |
| Free Cash Flow | -$122.5M | — | -99.0% |
| +158.1% |
| Stockholders' Equity | $545.9M | -17.1% | +58.5% |